Clinical Practice Guidelines

Garbe C. , Buttner P. , Weiss J. Risk factors for developing cutaneous melanoma and criteria for identifying persons at risk: multicenter case-control study of the Central Malignant Melanoma Registry of the German Dermatological Society. J Invest Dermatol. 1994; 102: 695–699.

Kopf A. , Marghoob A. , Slade J. Basal and squamous cell carcinomas: risk factors for cutaneous malignant melanoma. Presented at the Sixth World Congress on Cancers of the Skin; September 16–17, 1885; Buenos Aires, Argentina.

Elder D.E. , Goldman L.I. , Goldman S.C. Dysplastic nevus syndrome: a phenotypic association of sporadic cutaneous melanoma. Cancer. 1980; 46: 1787–1794.

Kamb A. , Shattuck-Eidens D. , Eeles R. Analysis of the p16 gene (CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locus. Nat Genet. 1994; 8: 23–26.

Rigel D.S. , Friedman R. , Kopf A. Importance of complete skin exam for the detection of malignant melanoma. J Am Acad Dermatol. 1986; 14: 857–860.

Veronesi U. , Cascinelli N. Narrow excision (1-cm margin): a safe procedure for thin cutaneous melanoma. Arch Surg. 1991; 126: 438–441.

Balch C.H. , Urist M.M. , Karakousis C.P. Efficacy of 2-cm surgical margins for intermediate-thickness melanoma (1 to 4 mm): results of a multi-institutional randomized surgical trial. Ann Surg. 1993; 218: 267–269.

Norman J. , Cruse C.W. , Espinosa C. Redefinition of cutaneous lymphatic drainage with the use of lymphoscintigraphy for malignant melanoma. Am J Surg. 1991; 162: 432–437.

Reintgen D.S. , Cruse C.W. , Wells K. The orderly progression of melanoma nodal metastases. Ann Surg. 1994; 220: 759–767.

Multicenter Selective Lymphadenectomy Trial. National Cancer Institute Grant No. PO1 CA29605-12.

Balch C.M. , Soong S.J. , Bartolucci A. Efficacy of an elective lymph node dissection of 1 to 4 mm thick melanomas for patients 60 years of age and younger. Ann Surg. 1996; 224: 255–266.

Buzaid A.C. , Tinoco L. , Ross M. Role of CT scans in the staging of melanoma patients with local-regional disease. Proc Annu Meet Am Soc Clin Oncol. 1995; 14: 411. Abstract A1303.

Ang K.K. , Byers R.M. , Peters L.J. Regional radiotherapy as adjuvant treatment for head and neck malignancy melanoma. Arch Otolaryngol Head Neck Surg. 1990; 116: 169–172.

Kirkwood J.M. , Strawderman M.H. , Ernstoff M.S. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial 1684. J Clin Oncol. 1996; 14: 7–17.

Amer M.H. , Al-Sarraf M. , Baker L.H. Malignant melanoma and central nervous system metastases: incidence, diagnosis, treatment and survival. Cancer. 1978; 42: 660–668.

Del Prete S.A. , Maurer L.H. , O'Donnell J. Combination chemotherapy with cisplatin, carmustine, dacarbazine, and tamoxifen in metastatic melanoma. Cancer Treat Rep. 1984; 68: 1403–1405.

Seigler H.F. , Lucas V.S. Jr , Pickett N.J. DTIC, CCNU, bleomycin and vincristine (BOLD) in metastatic melanoma. Cancer. 1980; 46: 2346–2348.

Krementz E.T. , Ryan R.F. , Muchmore J.H. Hyperthermic regional perfusion for melanoma of the limbs. In: Balch C.M. , Houghton A.N. , Milton G.W. , eds. Cutaneous Melanoma. 2nd ed. Philadelphia, Pa: JB Lippincott; 1992: 403.

Brobeil A. , Rapaport D. , Wells K. Multiple primary melanomas: implications for screening and follow-up programs for melanoma. Ann Surg Oncol. 1997; 4: 19–23.

Reintgen D.S. , Vollmer R. , Tso C.Y. Prognosis for recurrent stage I malignant melanoma. Arch Surg. 1987; 122: 1338–1342.